Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae

Matthew C. Canver, Michael J. Satlin, Lars F. Westblade, Barry N. Kreiswirth, Liang Chen, Amy Robertson, Kathy Fauntleroy, Marisa La Spina, Katrina Callan, Stephen G. Jenkins

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) strains are an urgent public health threat. We evaluated the in vitro activities of 19 antimicrobial agents, including imipenem-relebactam, against (i) 106 CRE bloodstream isolates that primarily expressed Klebsiella pneumoniae carbapenemase (KPC) and (ii) 20 OXA-48-like-expressing CRE isolates. Ninety-five percent of CRE bloodstream isolates were susceptible to imipenem-relebactam. In contrast to their comparable activities against KPC-producing CRE strains, ceftazidime-avibactam was more active in vitro against OXA-48-like CRE strains than was imipenem-relebactam (90% susceptible versus 15% susceptible).

Original languageEnglish (US)
Article numbere00672-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number9
DOIs
StatePublished - 2019

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Keywords

  • Carbapenem-resistant Enterobacteriaceae
  • Ceftazidime-avibactam
  • Imipenem-relebactam

Fingerprint

Dive into the research topics of 'Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this